Tracy Rubin

Cooley advised Lacework, a data-driven cloud security company, on its definitive agreement to be acquired by Fortinet (Nasdaq: FTNT), the global cybersecurity leader driving the convergence of networking and security.

Cooley advised AuditBoard, a leading connected risk platform transforming audit, risk, compliance, and environmental, social and governance (ESG) management, on its agreement to be acquired for more than $3 billion by Hg, an experienced and leading global investor in compliance, risk and accounting software over the last 20 years.

Cooley advised Freshworks (Nasdaq: FRSH), a company that creates artificial intelligence-boosted business software for IT, customer support, sales, and marketing teams to make them more efficient and deliver more value for immediate business impact, on its agreement and plan of merger with D42 Parent (Device42), pursuant to which Freshworks – through its wholly owned subsidiary, Doppler Merger Sub –will acquire all of the outstanding equity interests of Device42 for an aggregate purchase price of approximately $230 million.Cooley advised Freshworks (Nasdaq: FRSH), a company that creates artificial intelligence-boosted business software for IT, customer support, sales, and marketing teams to make them more efficient and deliver more value for immediate business impact, on its agreement and plan of merger with D42 Parent (Device42), pursuant to which Freshworks – through its wholly owned subsidiary, Doppler Merger Sub –will acquire all of the outstanding equity interests of Device42 for an aggregate purchase price of approximately $230 million.

Cooley advised Rubicon Technology Partners – a Boulder, Colorado-based private equity firm focused exclusively on investing in and growing software companies – on its majority strategic investment in Vimly Benefit Solutions, a leader in the benefits administration space.

Cooley advised Carmot Therapeutics, a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes, on its definitive merger agreement in which Roche will acquire Carmot.